A synthetic lethal screen identifies DNA repair pathways that sensitize cancer cells to combined ATR inhibition and cisplatin treatments

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Mohni, Kareem N ^a   Thompson, Petria S ^a   Luzwick, Jessica W ^a   Glick, Gloria G ^a   Pendleton, Christopher S ^a   Lehmann, Brian D ^a   Pietenpol, Jennifer A ^a   Cortez, David ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATM PROTEIN; ATR INHIBITOR; ATR PROTEIN; CISPLATIN; DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FUSED IN SARCOMA PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; UNCLASSIFIED DRUG; XRCC1 PROTEIN; 3-AMINO-6-(4-(METHYLSULFONYL)PHENYL)-N-PHENYLPYRAZINE-2-CARBOXAMIDE; ATR PROTEIN, HUMAN; DNA DIRECTED DNA POLYMERASE; DNA POLYMERASE ZETA; PYRAZINE DERIVATIVE; SIGNAL PEPTIDE; SMALL INTERFERING RNA; SULFONE; TP53BP1 PROTEIN, HUMAN; TUMOR SUPPRESSOR P53 BINDING PROTEIN 1;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DRUG POTENTIATION; HOMOLOGOUS RECOMBINATION; HUMAN; IC50; MISMATCH REPAIR; PATIENT SELECTION; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENE LIBRARY; HCT 116 CELL LINE; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DNA REPAIR; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE LIBRARY; HCT116 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PYRAZINES; RNA, SMALL INTERFERING; SULFONES; TUMOR SUPPRESSOR P53-BINDING PROTEIN 1;

EID: 84930664425     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125482     Document Type: Article

References (52)

1. Telli ML, Ford JM. Novel treatment approaches for triple-negative breast cancer. Clinical breast cancer. 2010; 10 Suppl 1:E16-22. doi: 10.3816/CBC.2010.s.003 PMID: 20587403.
2. Guler G, Himmetoglu C, Jimenez RE, Geyer SM, Wang WP, Costinean S, et al. Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features. Breast Cancer Res Treat. 2011; 129(2):421-32. doi: 10.1007/s10549-010-1248-6 PMID: 21069451; PubMed Central PMCID: PMC3677189.
3. Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, et al. Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin Cancer Res. 2010; 16(19):4702-10. doi: 10.1158/1078-0432.CCR-10-0939 PMID: 20858840; PubMed Central PMCID: PMC2948607.
4. Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 489(7417):519-25. doi: 10.1038/nature11404 PMID: 22960745; PubMed Central PMCID: PMC3466113.
5. Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A, Soria JC. The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nature reviews Clinical oncology. 2012; 9(3):144-55. doi: 10.1038/nrclinonc.2012.3 PMID: 22330686.
6. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. The oncologist. 2011; 16 Suppl 1:1-11. doi: 10.1634/theoncologist.2011-S1-01 PMID: 21278435.
7. Di Cosimo S, Baselga J. Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. Nature reviews Clinical oncology. 2010; 7(3):139-47. doi: 10.1038/nrclinonc.2009.234 PMID: 20125090.
8. Cufer T, Ovcaricek T, O'Brien ME. Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. Eur J Cancer. 2013; 49(6):1216-25. doi: 10.1016/j.ejca.2012.11.021 PMID: 23265700.
9. Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol. 2008; 9(8):616-27. Epub 2008/07/03. doi: 10.1038/nrm2450 PMID: 18594563; PubMed Central PMCID: PMC2663384.
10. Aguilera A, Gomez-Gonzalez B. Genome instability: a mechanistic view of its causes and consequences. Nature reviews Genetics. 2008; 9(3):204-17. doi: 10.1038/nrg2268 PMID: 18227811.
11. Branzei D, Foiani M. Maintaining genome stability at the replication fork. Nat Rev Mol Cell Biol. 2010; 11(3):208-19. doi: 10.1038/nrm2852 PMID: 20177396.
12. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005; 434(7035):864-70. doi: 10.1038/nature03482 PMID: 15829956.
13. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005; 434(7035):907-13. doi: 10.1038/nature03485 PMID: 15829965.
14. Bartek J, Bartkova J, Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene. 2007; 26(56):7773-9. doi: 10.1038/sj.onc.1210881 PMID: 18066090.
15. Charrier JD, Durrant SJ, Golec JM, Kay DP, Knegtel RM, MacCormick S, et al. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. J Med Chem. 2011; 54(7):2320-30. doi: 10.1021/jm101488z PMID: 21413798.
16. Hall AB, Newsome D, Wang Y, Boucher DM, Eustace B, Gu Y, et al. Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget. 2014; 5(14):5674-85. PMID: 25010037.
17. Foote KM, Blades K, Cronin A, Fillery S, Guichard SS, Hassall L, et al. Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-y l}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. J Med Chem. 2013; 56(5):2125-38. doi: 10.1021/jm301859s PMID: 23394205.
18. Mohni KN, Kavanaugh GM, Cortez D. ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency. Cancer Res. 2014; 74(10):2835-45. doi: 10.1158/0008-5472.CAN-13-3229 PMID: 24662920; PubMed Central PMCID: PMC4043842.
19. Reaper PM, Griffiths MR, Long JM, Charrier JD, Maccormick S, Charlton PA, et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nature chemical biology. 2011; 7(7):428-30. doi: 10.1038/nchembio.573 PMID: 21490603.
20. Sultana R, Abdel-Fatah T, Perry C, Moseley P, Albarakti N, Mohan V, et al. Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells. PLoS One. 2013; 8(2):e57098. doi: 10.1371/journal.pone.0057098 PMID: 23451157; PubMed Central PMCID: PMC3581581.
21. Toledo LI, Murga M, Zur R, Soria R, Rodriguez A, Martinez S, et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol. 2011; 18(6):721-7. Epub 2011/05/10. doi: 10.1038/nsmb.2076 PMID: 21552262.
22. Fokas E, Prevo R, Pollard JR, Reaper PM, Charlton PA, Cornelissen B, et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell death & disease. 2012; 3:e441. doi: 10.1038/cddis.2012.181 PMID: 23222511; PubMed Central PMCID: PMC3542617.
23. Schlacher K, Christ N, Siaud N, Egashira A, Wu H, Jasin M. Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell. 2011; 145(4):529-42. doi: 10.1016/j.cell.2011.03.041 PMID: 21565612; PubMed Central PMCID: PMC3261725.
24. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, Kunkel TA, et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res. 1994; 54(16):4308-12. Epub 1994/08/15. PubMed 8044777. PMID: 8044777
25. Umar A, Koi M, Risinger JI, Glaab WE, Tindall KR, Kolodner RD, et al. Correction of hypermutability, N-methyl-N′-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res. 1997; 57(18):3949-55. Epub 1997/10/27. PMID: 9307278.
26. Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013; 19(18):5003-15. doi: 10.1158/1078-0432.CCR-13-1391 PMID: 23881923.
27. Couch FB, Bansbach CE, Driscoll R, Luzwick JW, Glick GG, Betous R, et al. ATR phosphorylates SMARCAL1 to prevent replication fork collapse. Genes Dev. 2013; 27(14):1610-23. doi: 10.1101/gad.214080.113 PMID: 23873943.
28. Prichard MN, Shipman C Jr. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 1990; 14(4-5):181-205. PMID: 2088205.
29. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacological reviews. 1995; 47(2):331-85. PMID: 7568331.
30. Elion GB, Singer S, Hitchings GH. Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J Biol Chem. 1954; 208(2):477-88. PMID: 13174557.
31. Wang H, Wang H, Powell SN, Iliakis G, Wang Y. ATR affecting cell radiosensitivity is dependent on homologous recombination repair but independent of nonhomologous end joining. Cancer Res. 2004; 64(19):7139-43. doi: 10.1158/0008-5472.CAN-04-1289 PMID: 15466211.
32. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434(7035):913-7. doi: 10.1038/nature03443 PMID: 15829966.
33. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035):917-21. doi: 10.1038/nature03445 PMID: 15829967.
34. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012; 72(21):5588-99. doi: 10.1158/0008-5472.CAN-12-2753 PMID: 23118055; PubMed Central PMCID: PMC3528345.
35. Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R, et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 2008; 27(9):1368-77. doi: 10.1038/emboj.2008.61 PMID: 18388863; PubMed Central PMCID: PMC2374839.
36. Huntoon CJ, Flatten KS, Wahner Hendrickson AE, Huehls AM, Sutor SL, Kaufmann SH, et al. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res. 2013; 73(12):3683-91. doi: 10.1158/0008-5472.CAN-13-0110 PMID: 23548269; PubMed Central PMCID: PMC3687010.
37. Heacock ML, Stefanick DF, Horton JK, Wilson SH. Alkylation DNA damage in combination with PARP inhibition results in formation of S-phase-dependent double-strand breaks. DNA Repair (Amst). 2010; 9(8):929-36. doi: 10.1016/j.dnarep.2010.05.007 PMID: 20573551; PubMed Central PMCID: PMC2914189.
38. Horton JK, Stefanick DF, Naron JM, Kedar PS, Wilson SH. Poly(ADP-ribose) polymerase activity prevents signaling pathways for cell cycle arrest after DNA methylating agent exposure. J Biol Chem. 2005; 280(16):15773-85. doi: 10.1074/jbc.M413841200 PMID: 15701627.
39. Kedar PS, Stefanick DF, Horton JK, Wilson SH. Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts. Molecular cancer research: MCR. 2012; 10(3):360-8. doi: 10.1158/1541-7786.MCR-11-0477 PMID: 22246237; PubMed Central PMCID: PMC3307909.
40. Knobel PA, Marti TM. Translesion DNA synthesis in the context of cancer research. Cancer cell international. 2011; 11:39. doi: 10.1186/1475-2867-11-39 PMID: 22047021; PubMed Central PMCID: PMC3224763.
41. Bunting SF, Callen E, Wong N, Chen HT, Polato F, Gunn A, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell. 2010; 141(2):243-54. Epub 2010/04/07. doi: 10.1016/j.cell.2010.03.012 PMID: 20362325; PubMed Central PMCID: PMC2857570.
42. Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A. 2011; 108(8):3406-11. doi: 10.1073/pnas.1013715108 PMID: 21300883; PubMed Central PMCID: PMC3044391.
43. Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol. 2010; 17(6):688-95. doi: 10.1038/nsmb.1831 PMID: 20453858; PubMed Central PMCID: PMC2912507.
44. Lukas C, Savic V, Bekker-Jensen S, Doil C, Neumann B, Pedersen RS, et al. 53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress. Nat Cell Biol. 2011; 13(3):243-53. doi: 10.1038/ncb2201 PMID: 21317883.
45. Harrigan JA, Belotserkovskaya R, Coates J, Dimitrova DS, Polo SE, Bradshaw CR, et al. Replication stress induces 53BP1-containing OPT domains in G1 cells. J Cell Biol. 2011; 193(1):97-108. doi: 10.1083/jcb.201011083 PMID: 21444690; PubMed Central PMCID: PMC3082192.
46. Kotov IN, Siebring-van Olst E, Knobel PA, van der Meulen-Muileman IH, Felley-Bosco E, van Beusechem VW, et al. Whole genome RNAi screens reveal a critical role of REV3 in coping with replication stress. Molecular oncology. 2014. doi: 10.1016/j.molonc.2014.07.008 PMID: 25113059.
47. Bhat A, Andersen PL, Qin Z, Xiao W. Rev3, the catalytic subunit of Polzeta, is required for maintaining fragile site stability in human cells. Nucleic Acids Res. 2013; 41(4):2328-39. doi: 10.1093/nar/gks1442 PMID: 23303771; PubMed Central PMCID: PMC3575803.
48. Knobel PA, Kotov IN, Felley-Bosco E, Stahel RA, Marti TM. Inhibition of REV3 expression induces persistent DNA damage and growth arrest in cancer cells. Neoplasia. 2011; 13(10):961-70. PMID: 22028621; PubMed Central PMCID: PMC3201572.
49. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer discovery. 2012; 2(5):401-4. doi: 10.1158/2159-8290.CD-12-0095 PMID: 22588877; PubMed Central PMCID: PMC3956037.
50. Morelli C, Karayianni E, Magnanini C, Mungall AJ, Thorland E, Negrini M, et al. Cloning and characterization of the common fragile site FRA6F harboring a replicative senescence gene and frequently deleted in human tumors. Oncogene. 2002; 21(47):7266-76. doi: 10.1038/sj.onc.1205573 PMID: 12370818.
51. Neboori HJ, Haffty BG, Wu H, Yang Q, Aly A, Goyal S, et al. Low p53 binding protein 1 (53BP1) expression is associated with increased local recurrence in breast cancer patients treated with breast-conserving surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 2012; 83(5):e677-83. doi: 10.1016/j.ijrobp.2012.01.089 PMID: 22520477.
52. Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Molecular cancer therapeutics. 2014; 13(2):433-43. doi: 10.1158/1535-7163.MCT-13-0803 PMID: 24356813; PubMed Central PMCID: PMC3946062.